Spots Global Cancer Trial Database for A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
Official Title: A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients With B-Cell Lymphomas
Study ID: NCT02395601
Conditions
Interventions
Study Description
Brief Summary: First in human, open-label, sequential dose escalation and expansion study of CPI-1205 in patients with progressive B-cell lymphomas. CPI-1205 is a small molecule inhibitor of EZH2.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Horizon Oncology Center, Lafayette, Indiana, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
John Theurer Cancer Center, Hackensack, New Jersey, United States
The Ohio State University James Cancer Hospital, Columbus, Ohio, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
